agonistas de receptores glp 1 GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus Agonistas del receptor GLP-1 |

Stuber et al., 2025)

Routine consultation with your healthcare provider is appropriate when: Taste changes lead to significant unintentional weight loss beyond treatment goals Nutritional intake becomes severely restricted, raising concerns about deficiencies Taste alterations persist beyond 8-12 weeks without improvement Quality of life is substantially impacted by food aversions or taste disturbances New or worsening symptoms develop, such as persistent metallic taste with other concerning features Your provider can assess whether taste changes represent expected treatment effects or require investigation for alternative causes

Were here to help you help your patients

Furthermore, M1 macrophage-derived exosomes reduce E-cadherin expression in the intestinal barrier by secreting miR-21a-5p, which exacerbates intestinal inflammation in UC model mice and destroys the structure and function of the intestinal barrier